STAT+: GSK lays out plans to cut costs, pursue more late-stage drug trials

STAT PlusPharma GSK lays out plans to cut costs, pursue more late-stage drug trials CEO Luke Miels has set out to make the company faster and more agile Manage alerts for this article Email this article Share this article By Andrew JosephJuly 28, 2026 Europe Correspondent Andrew Joseph[email protected]Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — Half a year into taking over the job, GSK CEO Luke Miels on Tuesday laid out his plans to turn the U.K.

pharma giant into a more agile company with years of growth ahead. A key step, Miels said, will be a three-year campaign to generate 1.9 billion pounds (about $2.5 billion) in annual savings by 2029, much of which will be reinvested to advance the company’s late-stage pipeline. The company also now plans to start at least 20 Phase 3 trials this year, up from the 10 that it had disclosed at the beginning of 2026.

Advertisement “We are step-by-step building a set of potential best-in-class products across our core therapy areas,” Miels said, a list that includes some newer target areas — like oncology and liver disease — as well as longtime GSK focuses like vaccines and HIV. Miels would not say Tuesday how many jobs would be cut under the savings drive. STAT+ Exclusive Story Already have an account?

Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%!

Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In GSK, Pharmaceuticals, STAT+ Submit a correction requestReprints Andrew Joseph Europe Correspondent Andrew covers the biopharma industry, scientific research, and public health across the continent.

You can reach Andrew confidentially on Signal at drewqjoseph.71. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended Biotech July 28, 2026 STAT Plus: FDA staff reiterate concerns about Replimune skin cancer treatment Pharmalot July 28, 2026 STAT Plus: Pharmalittle: We’re reading about FDA views on a Duchenne drug, GSK cost savings, and more Advertisement Health Tech Newsletter July 28, 2026 STAT Plus: Three questions with Whoop’s new CMO Morning Rounds July 28, 2026 Anthony Fauci’s pandemic-era diary entries Biotech July 28, 2026 STAT Plus: Preliminary trial results suggest a path to a safer Alzheimer’s treatment Subscriber Picks